Related Experiment Video

Updated: Aug 13, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

[Hypoglycemia and microgastria]

J J Choulot

    Archives Francaises De Pediatrie
    |June 1, 1978
    PubMed

    Insights

    Hypoglycemic convulsions in an infant were linked to suspected dumping syndrome due to a small stomach. Continuous intragastric feeding led to the child

    Area of Science:

    • Pediatric Gastroenterology
    • Neonatal Medicine

    Background:

    • Infantile hypoglycemia can present with severe neurological symptoms like seizures.
    • Dumping syndrome, a condition typically seen post-gastric surgery, involves rapid gastric emptying.

    Observation:

    • A 5 1/2-month-old infant experienced hypoglycemic convulsions.
    • Physical examination revealed a small stomach.
    • The infant was managed with continuous intragastric infusion feeding.

    Findings:

    • The clinical presentation and small stomach size suggested a diagnosis of dumping syndrome in this infant.
    • Continuous intragastric infusion feeding was an effective management strategy.

    Implications:

    • This case highlights the possibility of dumping syndrome in infants presenting with hypoglycemia and gastric abnormalities.
    • Continuous intragastric feeding can be a successful therapeutic approach for infants with this condition.
    • Further research into the etiology and management of infantile dumping syndrome is warranted.

    More Related Videos

    Assessment of Gastric Emptying in Non-obese Diabetic Mice Using a [13C]-octanoic Acid Breath Test12:24

    Assessment of Gastric Emptying in Non-obese Diabetic Mice Using a [13C]-octanoic Acid Breath Test

    Published on: March 23, 2013

    Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice07:35

    Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice

    Published on: January 26, 2024

    Related Concept Videos

    Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

    Oral Hypoglycemic Agents: Biguanides and Glitazones

    Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
    Oral Hypoglycemic Agents: Glinides01:06

    Oral Hypoglycemic Agents: Glinides

    Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

    α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
    Acarbose and miglitol are typically...
    Hypoglycemia and Glucagon01:15

    Hypoglycemia and Glucagon

    Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
    Hypoglycemia01:26

    Hypoglycemia

    Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
    Hyperglycemia01:29

    Hyperglycemia

    Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...